Small extracellular vesicles (sEVs) from mesenchymal stromal/stem cells (MSCs) are
transiting rapidly towards clinical applications. However, discrepancies and controversies …

Critical limb ischemia (CLI) constitutes the most severe form of peripheral arterial disease
(PAD), it is characterized by progressive blockade of arterial vessels, commonly correlated …

Therapeutic angiogenesis with mesenchymal stem cells (MSCs) is promising for the clinical
treatment of peripheral artery disease (PAD). However, the heterogeneous proangiogenic …

Peripheral artery disease (PAD) is a vascular disorder caused by occlusive atherosclerosis,
which commonly impairs blood flow to the lower extremities. The prevalence of PAD is …

Lower extremity chronic wounds (LECWs) commonly occur in patients with diabetes mellitus
(DM) and peripheral arterial disease (PAD). Autologous stem cell therapy (ASCT) has …

Background Autologous cell therapy (ACT) is a new treatment method for patients with
diabetes and no-option chronic limb-threatening ischemia (NO-CLTI). We aimed to assess …

Mesenchymal stem cell (MSC) therapy represents an alternative approach for tissue
regeneration and inflammation control. In spite of a huge amount of preclinical data that has …

As an evidence-based performance, the rising incidence of various ischemic disorders has
been observed across many nations. As a result, there is a growing need for the …

We propose the use of a peripheral blood mononuclear cell therapy based on cell NGAL
release to be used in the clinical setting for acute kidney injury (AKI) and the derived fibrosis …

Background The regeneration response of the skin to mechanical stretching in vivo has
been explored in reconstructive surgery to repair large-scale deformities. The ability of the …